NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. In 2022, the company launched CosMxTM Spatial Molecular Imager, enabling the first high-plex in situ analysis platform to provide spatial multi-omics with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples at cellular and subcellular resolution. CosMx SMI is a flexible, spatial single-cell imaging platform that will drive deeper insights for cell atlasing, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker discovery. In 2022, AtoMx™ Spatial Informatics Platform (SIP), the only cloud-based, fully-integrated informatics platform for spatial biology, was also launched.
View Top Employees from NanoString Technologies, Inc.Website | http://www.nanostring.com |
Ticker | NSTG |
Revenue | $106 million |
Funding | $935.9 million |
Employees | 870 (870 on RocketReach) |
Founded | 2003 |
Address | 530 Fairview Avenue N Suite 2000, Seattle, Washington 98109, US |
Phone | (206) 378-6266 |
Fax | (206) 378-6288 |
Technologies |
JavaScript,
HTML,
PHP
+143 more
(view full list)
|
Industry | Biotechnology Research, Medical Devices & Equipment, Biotechnology, Gene Expression, miRNA, CNV and Single Cell Analysis, Manufacturing, Science and Engineering, Digital Genomics for Pathway-based Research, Health Diagnostics, Multiplexed Molecular Diagnostic Development, Health Care, General Purpose Reagents for Laboratory Use, Medical, Translational Cancer Genomics and Cancer Research |
Web Rank | 217209 |
Web Visits | 365670 |
Keywords | Translational Research |
Competitors | Asuragen, Biolin Scientific AB, Chronix Biomedical, Inc., Nanogen, QuantuMDx |
SIC | SIC Code 38 Companies, SIC Code 384 Companies |
NAICS | NAICS Code 33 Companies, NAICS Code 334 Companies |
Looking for a particular NanoString Technologies, Inc. employee's phone or email?
The NanoString Technologies, Inc. annual revenue was $106 million in 2024.
Brad Gray is the President and Chief Executive Officer of NanoString Technologies, Inc..
870 people are employed at NanoString Technologies, Inc..
NanoString Technologies, Inc. is based in Seattle, Washington.
The NAICS codes for NanoString Technologies, Inc. are [33, 334].
The SIC codes for NanoString Technologies, Inc. are [38, 384].